Clinical Trial Update: Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety and immunogenicity of new formulations of GSK's DTPa-HBV-IPV/Hib vaccine (DTPa-HBV-IPV/Hib, GSK217744).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-HBV-IPV/Hib vaccine (DTPa-HBV-IPV/Hib vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Poliomyelitis | Phase 2 | Status: COMPLETED | Results posted: 2014-06-06